The BEST + ICD Trial: Is ICD Also Effective in the Presence of Optimized β-Blocking Therapy?

  • R. Cappato
  • M. G. Bongiorni
  • M. Brignole
  • A. Capucci
  • F. Gaita
  • S. Mangiameli
  • A. S. Montenero
  • R. F. E. Pedretti
  • A. Raviele
  • J. Salerno-Uriarte
  • S. Sermasi
Conference paper


Total mortality and sudden death rates during the first year following an acute MI have significantly decreased in the past decade (from 2.8% and 7.1% to 1.9% and 3.0%, respectively) [1,2] as a result of modern therapy with thrombolytic agents [1–3], aspirin [4], β-blockers [5], angiotensin-converting enzyme (ACE) inhibitors [6], statines [7, 8], and revascularization procedures [9]. Nevertheless, approximately 10% of post-MI survivors remain at high risk of dying in the first months or years following hospital discharge (mortality > 25% at 2 years) [10]. This population accounts for a considerable proportion of deaths every year, approximately 37,500 cases in the USA and 3750 in Italy [11, 12]. Sudden death secondary to sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) accounts for about 50% of all deaths in these high-risk patients [13]. Identification and protection of post-MI patients who are predisposed to develop life-threatening ventricular arrhythmias during follow-up is crucial in order to reduce both sudden death and all-cause mortality.


Heart Rate Variability Acute Myocardial Infarction Ventricular Premature Beat Sustained Ventricular Arrhythmia Ventricular Late Potential 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Califf RM, White HD, Van de Werf F, Sadowski Z, Armstrong PW, Vahanian A, Simoons ML, Simes RJ, Lee KL, Topol EJ (1996) One-year results from the global utilization of streptokinase and TPA for occluded coronary arteries (GUSTO I) trial. Circulation 94:1233–1238PubMedCrossRefGoogle Scholar
  2. 2.
    Rouleau JL, Talajic M, Sussex B, Potvin L, Warnica W, Davies RF, Gardner M, Stewart D, Plante S, Dupuis R, Lauzon C, Ferguson J, Mikes E, Balnozan V, Savard P (1996) Myocardial infarction patients in the 1990s -their risk factors, stratification and survival in Canada: the Canadian Assessment of Myocardial Infarction (CAMI) study. J Am Coll Cardiol 27:1119–1127PubMedCrossRefGoogle Scholar
  3. 3.
    Volpi A, De Vita C, Franzosi MG, Geraci E, Maggioni AP, Mauri F, Negri E, Santoro E, Tavazzi L, Tognoni G (1993) Determinants of 6-month mortality in survivors of myocardial infarction after thrombolysis. Results of the GISSI-2 data base. Circulation 88:416–429Google Scholar
  4. 4.
    Antiplatelet Trialists Collaboration (1988) Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 296:320–331CrossRefGoogle Scholar
  5. 5.
    Yusuf S, Peto R, Lewis J, Collins R, Sleight P (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27:335–371PubMedCrossRefGoogle Scholar
  6. 6.
    Latini R, Maggioni AP, Fiather M, Sleight P, Tognoni G (1995) ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation 92:3132–3137Google Scholar
  7. 7.
    Scandinavian Simvastatin Survival Study Group (1994) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383–1389Google Scholar
  8. 8.
    Sacks MF, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica W, Arnold JMO, Wun CC, Davis BR, Braunwald E (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001–1009PubMedCrossRefGoogle Scholar
  9. 9.
    Michels KB, Yusuf S (1995) Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials. Circulation 91:476–485PubMedCrossRefGoogle Scholar
  10. 10.
    Raviele A, Bonso A, Gasparini G, Themistoclakis S (1998) Prophylactic implantation of implantable cardioverter/defibrillator in post-myocardial infarction patients. In: Vardas PE (ed) Cardiac arrhythmias, pacing and electrophysiology. Kluger Academic Publishers, Dordrecht, pp 305–310CrossRefGoogle Scholar
  11. 11.
    ACC/AHA practice guidelines for the management of patients with acute myocardial infarction (1996) J Am Coll Cardiol 28:1328–1428CrossRefGoogle Scholar
  12. 12.
    Feruglio GA, Vanuzzo D (1989) La cardiopatia ischemica in Italia: le dimensioni del problema. G Ital Cardiol 19:754–762PubMedGoogle Scholar
  13. 13.
    Uretsky BF, Sheahan RG (1997) Primary prevention of sudden cardiac death in heart failure: will the solution be shocking? J Am Coll Cardiol 30:1589–1597PubMedCrossRefGoogle Scholar
  14. 14.
    Pratt CM, Waldo AL, Camm AJ (1998) Can antiarrhythmic drugs survive survival trials? Am J Cardiol 81(6A):24D–34DPubMedCrossRefGoogle Scholar
  15. 15.
    Bigger JT, Fleiss JL, Kleiger R, Miller JP, Rolnitzky LM (1984) The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 69:250–258PubMedCrossRefGoogle Scholar
  16. 16.
    Mukharji J, Rude RE, Poole WK, Gustafson N, Thomas LJ, Strauss HW, Jaffe AS, Müller JE, Roberts R, Raabe DS, Croft CH, Passamani E, Braunwald E, Willerson JT (1984) Risk factors for sudden death after acute myocardial infarction: two-year follow-up. Am J Cardiol 54:31–36PubMedCrossRefGoogle Scholar
  17. 17.
    Kostis JB, Byington R, Friedman LM, Goldstein S, Furberg C (1987) Prognostic significance of ventricular ectopic activity in survivors of acute myocardial infarction. J Am Coll Cardiol 10:231–242PubMedCrossRefGoogle Scholar
  18. 18.
    Maggioni AP, Zuanetti G, Franzosi MG, Rovelli F, Santoro E, Staszewsky L, Tavazzi L, Tognoni G (1993) Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era. GISSI-2 results. Circulation 87:312–322Google Scholar
  19. 19.
    Denniss AR, Richards DA, Cody DV, Rüssel PA, Young AA, Cooper MJ, Ross DL, Uther JB (1986) Prognostic significance of ventricular tachycardia and fibrillation induced at programmed stimulation and delayed potentials detected on the signal-averaged electrocardiograms of survivors of acute myocardial infarction. Circulation 74:731–745PubMedCrossRefGoogle Scholar
  20. 20.
    McClements BM, Adgey AAJ (1993) Value of signal-averaged electrocardiography, radionuclide ventriculography, Holter monitoring and clinical variables for prediction of arrhythmic events in survivors of acute myocardial infarction in the thrombolytic era. J Am Coll Cardiol 21:1419–1427PubMedCrossRefGoogle Scholar
  21. 21.
    Cain ME, Anderson JL, Arnsdorf MF, Mason JW, Scheinman MM, Waldo AL (1996) ACC expert consensus document. Signal-averaged electrocardiography. J Am Coll Cardiol 27:238–249Google Scholar
  22. 22.
    Kleiger RE, Miller JP, Bigger JT, Moss AJ (1987) Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 59:256–262PubMedCrossRefGoogle Scholar
  23. 23.
    Farrell TG, Bashir Y, Cripps T, Malik M, Poloniecki J, Bennett ED, Ward DE, Camm AJ (1991) Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and signal-averaged electrocardiogram. J Am Coll Cardiol 18:687–697PubMedCrossRefGoogle Scholar
  24. 24.
    Hartikainen JEK, Malik M, Staunton A, Poloniecki J, Camm J (1996) Distinction between arrhythmic and nonarrhythmic death after acute myocardial infarction based on heart rate variability, signal-averaged electrocardiogram, ventricular arrhythmias and left ventricular ejection fraction. J Am Coll Cardiol 28:296–304PubMedCrossRefGoogle Scholar
  25. 25.
    Zuanetti G, Neilson JMM, Latini R, Santoro E, Maggioni AP, Ewing DJ (1996) Prognostic significance of heart rate variability in post-myocardial infarction patients in the fibrinolytic era. The GISSI-2 results. Circulation 94:432–436Google Scholar
  26. 26.
    La Rovere MT, Bigger JT, Marcus FI, Mortara A, Schwartz PJ (1998) Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet 351:478–484PubMedCrossRefGoogle Scholar
  27. 27.
    Schwartz PJ, Wolf S (1978) QT interval prolongation as predictor of sudden death in patients with myocardial infarction. Circulation 57:1074–1077PubMedCrossRefGoogle Scholar
  28. 28.
    Perkiömäki JS, Koistinen MJ, Yli-Mäyry S, Huikuri HV (1995) Dispersion of QT interval in patients with and without susceptibility to ventricular tachyarrhythmias after previous myocardial infarction. J Am Coll Cardiol 26:174–179PubMedCrossRefGoogle Scholar
  29. 29.
    Rosenbaum DS, Jackson LE, Smith JM (1994) Electrical alternans and vulnerability to ventricular arrhythmias. N Engl J Med 330:235–241PubMedCrossRefGoogle Scholar
  30. 30.
    Waspe LE, Seinfeld D, Ferrick A, Kim SG, Matos JD, Fisher JD (1985) Prediction of sudden death and spontaneous ventricular tachycardia in survivors of complicated myocardial infarction: value of the response to programmed stimulation using a maximum of three ventricular extrastimuli. J Am Coll Cardiol 5:1292–1301PubMedCrossRefGoogle Scholar
  31. 31.
    Wilber DJ, Olshansky B, Moran JF, Scanlon PJ (1990) Electrophysiologic testing and nonsustained ventricular tachycardia: use and limitation in patients with coronary artery disease and impaired ventricular function. Circulation 82:350–358PubMedCrossRefGoogle Scholar
  32. 32.
    Bourke JP, Richards DA, Ross DL, Wallace EM, McGuire MA, Uther JB (1991) Routine programmed electrical stimulation in survivors of acute myocardial infarction for prediction of spontaneous ventricular tachyarrhythmias during follow-up: results, optimal stimulation protocol and cost-effective screening. J Am Coll Cardiol 18:780–788PubMedCrossRefGoogle Scholar
  33. 33.
    Pedretti R, Etro MD, Laporta A, Sarzi Braga S, Caru B (1993) Prediction of late arrhythmic events after acute myocardial infarction from combined use of noninvasive prognostic variables and inducibility of sustained monomorphic ventricular tachycardia. Am J Cardiol 71:1131–1141PubMedCrossRefGoogle Scholar
  34. 34.
    Furberg CD (1983) Effect of antiarrhythmic drugs on mortality after myocardial infarction. Am J Cardiol 52:32C–36CPubMedCrossRefGoogle Scholar
  35. 35.
    The Cardiac Arrhythmia Suppression Trial (CAST) (1989) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321:406–412CrossRefGoogle Scholar
  36. 36.
    The Cardiac Arrhythmia Suppression Trial II Investigators (1992) Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 327:227–233CrossRefGoogle Scholar
  37. 37.
    Teo KK, Yusuf S, Furberg CD (1993) Role of antiarrhytmic prophylaxis in acute myocardial infarction. Review of clinical results. JAMA 270:1589–1595Google Scholar
  38. 38.
    Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP (1996) Effect of d-1 sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 348:7–12PubMedCrossRefGoogle Scholar
  39. 39.
    Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, Simon P (1997) Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 349:667–674PubMedCrossRefGoogle Scholar
  40. 40.
    Cairns JA, Connolly SJ, Roberts R, Gent M (1997) Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 349:675–682PubMedCrossRefGoogle Scholar
  41. 41.
    DIAMOND Study Group (1997) Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: rationale, design, and patient characteristics of the DIAMOND studies. Clin Cardiol 20:704–710CrossRefGoogle Scholar
  42. 42.
    Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M (1996) Improved survival with an implanted defìbrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 335:1933–1940PubMedCrossRefGoogle Scholar
  43. 43.
    GISSI (1996) Six-month effects of early treatment with lisinopril and transdermal glyceril trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 trial. J Am Coll Cardiol 27:337–344Google Scholar
  44. 44.
    Bigger JT, for the CABG Patch Trial Investigators (1997) Prophylactic use of implanted cardiac defìbrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med 337:1569–1575PubMedCrossRefGoogle Scholar
  45. 45.
    Copie X, Hnatkova K, Staunton A, Fei L, Camm AJ, Malik M (1996) Predictive power of increased heart rate versus depressed left ventricular ejection fraction and heart rate variability for risk stratification after myocardial infarction. Results of a twoyear follow-up study. J Am Coll Cardiol 27:270–276PubMedCrossRefGoogle Scholar
  46. 46.
    Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology (1996) Heart rate variability. Standards of measurement, physiological interpretation and clinical use. Circulation 93:1043–1065CrossRefGoogle Scholar
  47. 47.
    The Norwegian Multicenter Study Group (1981) Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304:801–807CrossRefGoogle Scholar
  48. 48.
    Beta-blocker Heart Attack Trial Research Group (1982) A randomized trial of propranolol in patients with acute myocardial infarction: mortality results. JAMA 247:1707–1714CrossRefGoogle Scholar
  49. 49.
    Viskin S, Kitzis I, Lev E, Zak Z, Zajarias A, Laniado S, Beihassen B (1995) Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. J Am Coll Cardiol 25:1327–1332PubMedCrossRefGoogle Scholar
  50. 50.
    Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Malik I, Nyberg G, Ryden L, Swedberg K, Vedin A, Waagstein F, Waidenstrom A, Waidenstrom J, Wedel H, Wilnelmsen L, Wilhelmsson C (1981) Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomized trial. Lancet 2:823–837PubMedCrossRefGoogle Scholar
  51. 51.
    Packer M, Bristow M, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart faüure. N Engl J Med 334:1349–1355PubMedCrossRefGoogle Scholar
  52. 52.
    The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI) (1985) A randomized placebo-controlled international trial. Eur Heart J 6:199–226Google Scholar
  53. 53.
    Di Pede F, Gasparini G, Raviele A, Piccolo E (1995) Studi elettrofìsiologici durante la fase acuta delPinfarto miocardico. Può essere prognostico? In: Caturelli G (ed) Cura intensiva cardiologica. CESI, Rome, pp 495–498Google Scholar
  54. 54.
    Whitehead J (1992) The design and analysis of sequential clinical trials, 2nd edn. Ellis Horwood, ChichesterGoogle Scholar

Copyright information

© Springer-Verlag Italia 2000

Authors and Affiliations

  • R. Cappato
    • 1
  • M. G. Bongiorni
  • M. Brignole
  • A. Capucci
  • F. Gaita
  • S. Mangiameli
  • A. S. Montenero
  • R. F. E. Pedretti
  • A. Raviele
  • J. Salerno-Uriarte
  • S. Sermasi
  1. 1.2. Med. Abt. AK St. GeorgHamburgGermany

Personalised recommendations